Avicenna Holdings Limited has been acquired by Juno Health
The shareholders of Avicenna Holdings Limited have sold the business to Juno Health.
Based in the UK, Avicenna comprises 21 pharmacies, as well as a buying group operation serving more than 1,000 independent pharmacies.
Juno Health is a UK-based company that operates a chain of pharmacy stores. The community pharmacies will be integrated into Juno’s existing chain with the buying group continuing to be run by Salim Jetha, Avicenna CEO. It will become the industry-leading buying and support group for independent pharmacies across the UK. Juno has considerable experience in the sector and the combination of Avicenna resources and expertise will support the independent pharmacy sector and improve membership benefits.
Richard Smith, Chairman at Juno Health, said: “Avicenna is a well-established business delivering clear benefits to its members. It is one of the most recognizable brands among independent pharmacists and extremely well respected.”
Oaklins Cavendish, based in the UK, advised the shareholders of Avicenna on the sale of the business to Juno Health.
Prata med transaktionsteamet
Relaterade affärer
Afric Phar has been acquired by Pharma Capital
Pharma Capital S.A. has acquired a significant stake in the Moroccan pharmaceutical group Afric Phar, which includes leading companies Afric Phar, Pharmis and Partner Lab, from the Chaoui family, in one of the largest transactions in the Moroccan pharmaceutical sector.
Lär dig merDen Berk Délice accelerates growth through strategic partnership
Den Berk Délice, a leading Belgian grower of specialty tomatoes, has entered a strategic partnership with Egeria, an independent investment firm, to realize its next growth phase.
Lär dig merXiel Limited has been acquired by MIS Healthcare
MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.
Lär dig mer